Dear Editor, I read with interest the recently published article by Selimzade et al,1 entitled “Thyroid- Stimulating Hormone Suppression Therapy and Its Association with Anxiety, Depression, Hypomania, and Quality of Life in Differentiated Thyroid Cancer.” I congratulate the authors and would like to highlight several points relevant to the interpretation of the findings. Cite this article as: Öztürk HD. Thyroidstimulating hormone suppression and psychiatric findings: considerations for interpretation. Endocrinol Res Pract. Published online November 3, 2026. doi: 10.5152/erp.2026.261130.
Objective: The aims of this study were to determine the prevalence of anxiety disorder in patients with primary hyperaldosteronism (PA), to compare it with patients diagnosed with essential hypertension (EHT) after exclusion of secondary causes, and to evaluate the association between treatment modalities for PA and changes in the course of anxiety disorder.Methods: A total of 133 patients were included in this retrospective study, comprising 90 patients with PA and 43 patients with EHT. Among patients with PA, 39 received surgical treatment and 51 received medical therapy. The PA and EHT groups were compared with respect to demographic, clinical, and laboratory characteristics. Within the PA group, the relationship between treatment modality and changes in anxiety disorder management during follow-up was also analyzed.Results: The prevalence of anxiety disorder was significantly higher in the PA group compared with the EHT group (27.8% vs. 9.3%, p = 0.029). Patients with PA were younger and more frequently male. Serum aldosterone levels and the aldosterone-to-renin ratio were significantly higher, whereas renin and potassium levels were significantly lower in the PA group (all p < 0.05). Among patients with PA, no significant differences were observed in most clinical and laboratory parameters between those with and without anxiety disorder. Discontinuation of anxiety disorder treatment was observed more frequently in patients who underwent surgical treatment compared with those receiving medical therapy.Conclusions: These findings suggest that anxiety disorder accompanying hypertension may be more frequently observed in patients with PA and that there may be an association between treatment modality and psychiatric outcomes.
Background and Objectives: This study aimed to evaluate short-term changes in sexual function, sexual satisfaction, sexual quality of life, and depressive symptoms during GLP-1-based therapy in premenopausal women with obesity and to investigate whether changes in sexual quality of life were associated with weight loss and changes in depressive symptoms. Materials and Methods: This single-center retrospective observational study included 50 premenopausal women receiving semaglutide, tirzepatide, or liraglutide for obesity. Arizona Sexual Experience Scale (ASEX), Golombok–Rust Inventory of Sexual Satisfaction (GRISS), Sexual Quality of Life—Female (SQoL-F), and Beck Depression Inventory (BDI) scores were assessed at baseline and at months 1 and 3. Associations of changes in sexual quality of life with age, baseline BMI, percentage weight loss (%WL), and changes in depressive symptoms were examined. Results: At 3 months, body weight decreased significantly from 103.35 to 95.30 kg (p < 0.001), while SQoL-F scores increased from 70.0 to 83.33 (p < 0.001) and BDI scores decreased from 13.0 to 8.0 (p = 0.001). No significant changes were observed in ASEX (p = 0.128) or GRISS (p = 0.084) scores. The magnitude of improvement in SQoL-F was not significantly associated with %WL (ρ = 0.080; p = 0.580) or changes in BDI scores (ρ = 0.249; p = 0.081). Exploratory analyses showed no significant between-treatment differences in changes in psychosexual outcomes. Conclusions: During 3 months of GLP-1-based therapy in premenopausal women with obesity, sexual quality of life and depressive symptoms improved, whereas no significant changes were observed in sexual function or sexual satisfaction. Given the observational design, absence of a control group, and concurrent lifestyle interventions, these improvements cannot be attributed specifically to GLP-1-based therapy. Controlled prospective studies with longer follow-up are warranted.
Backgrounds/Objectives: Subsyndromal depressive symptoms are common during inter-episode periods in bipolar disorder and have been associated with functional impairment. This study aimed to examine their clinical and psychosocial correlates across multiple domains and to evaluate depressive symptom severity from both categorical and dimensional perspectives. Methods: This cross-sectional study included 133 outpatients with bipolar I disorder who had experienced no syndromal mood episode during the preceding six months. Patients were classified as having subsyndromal depressive symptoms (n = 61; HDRS 8–14 and YMRS < 8) or as euthymic (n = 72; HDRS < 8 and YMRS < 8). Clinical characteristics, functioning, impulsivity, internalized stigma, and anxiety were assessed. Results: The subsyndromal depressive group had higher total and depressive episode counts and more frequent histories of antidepressant-induced manic switch and suicide attempt than the euthymic group (all p < 0.05). They also showed lower functioning and higher impulsivity, internalized stigma, and anxiety (all p < 0.05). Within the subsyndromal depressive group, depressive symptom severity was associated with the number of depressive episodes and specific domains of functioning, impulsivity, internalized stigma, and anxiety. Conclusions: Subsyndromal depressive symptoms were associated with clinically relevant differences across multiple clinical and psychosocial domains during inter-episode periods in bipolar I disorder. The associations observed across specific domains also support considering depressive symptom severity dimensionally alongside categorical assessment.